Form 4

United States Securities and Exchange Commission
Washington, D.C. 20549

Statement of Changes in Beneficial Ownership of Securities

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   Gerberding Julie L.
   (Last) (First) (Middle)
   MERCK & CO., INC. 2000 GALLOPING HILL ROAD
   KENILWORTH, NJ 07033

2. Issuer Name and Ticker or Trading Symbol
   Merck & Co., Inc. [ MRK ]

3. Date of Earliest Transaction (MM/DD/YYYY)
   7/17/2020

5. Relationship of Reporting Person(s) to Issuer
   (Check all applicable)
   - Director
   - 10% Owner
   - Officer (give title below)
   - Other (_X_)
   EVP Strat Comm, GI Pub Policy

6. Individual or Joint/Group Filing
   (Check Applicable Line)
   - Form filed by One Reporting Person (_X_)
   - Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Trans. Date</th>
<th>Deemed Execution Date, if any</th>
<th>Trans. Code (Instr. 8)</th>
<th>Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>7/17/2020</td>
<td>M</td>
<td>18111</td>
<td>A</td>
<td>$0</td>
<td>62862.138</td>
</tr>
<tr>
<td>Common Stock</td>
<td>7/17/2020</td>
<td>S</td>
<td>18111</td>
<td>D</td>
<td>$80.00</td>
<td>44751.138</td>
</tr>
<tr>
<td>Common Stock</td>
<td>7/17/2020</td>
<td>S</td>
<td>18174</td>
<td>D</td>
<td>$80.0097</td>
<td>26577.138</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| Title of Derivative Security | Trans. Date | Deemed Execution Date, if any | Trans. Code (Instr. 8) | Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | Date Exercisable and Expiration Date | Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | Price of Derivative Security (Instr. 5) | Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Nature of Indirect Beneficial Ownership (Instr. 4) |
|------------------------------|-------------|-------------------------------|------------------------|-------------------------------------------------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------|------------------------------------------------|}
| Stock Option (Right to Buy)  | $54.68      | 7/17/2020                     | M                      | 18111                                                                               | 5/9/2026                          | Common Stock 18111 $0 0 0                                                                   | D                                | D                                                                                               | D                                               | D                                              |

Explanation of Responses:

(1) The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.0450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
(3) Holdings include shares acquired in dividend reinvestment transactions.

Reporting Owners

Reporting Owner Name / Address
Gerberding Julie L.
MERCK & CO., INC.
2000 GALLOPING HILL ROAD
KENILWORTH, NJ 07033

Relationships
Director 10% Owner Officer Other
10% Owner EVP Strat Comm, GI Pub Policy

Signatures

Faye C. Brown as Attorney-in-Fact for Julie L. Gerberding 7/20/2020

Signature of Reporting Person
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.